Formulation of boronic acid compounds

Details Formulation of boronic acid compounds Formulation of boronic acid compounds

2006-09-19

2006-09-19

Wilson, James O. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S017100, C514S002600, C514S018700, C514S019300, C514S064000, C544S229000, C530S320000

Reexamination Certificate

active

07109323

ABSTRACT:
The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.

REFERENCES:
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 5106948 (1992-04-01), Kinder et al.
patent: 5169841 (1992-12-01), Kleeman et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5492900 (1996-02-01), LaHann
patent: 5574017 (1996-11-01), Gutheil
patent: 5780454 (1998-07-01), Adams et al.
patent: 5935944 (1999-08-01), LaHann
patent: 5990083 (1999-11-01), Iqbal et al.
patent: 6066730 (2000-05-01), Adams et al.
patent: 6083903 (2000-07-01), Adams et al.
patent: 6169076 (2001-01-01), Shull et al.
patent: 6297217 (2001-10-01), Adams et al.
patent: 6699835 (2004-03-01), Plamondon et al.
patent: 6713446 (2004-03-01), Gupta
patent: 2002/0169114 (2002-11-01), Gupta
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/57887 (2000-10-01), None
patent: WO 01/02424 (2001-01-01), None
patent: WO 02/059130 (2002-01-01), None
Ciechanover, “The Ubiquitin-Proteasome Proteolytic Pathway,”Cell, vol. 79, pp. 13-21 (Oct. 7, 1994).
Gennaro, “Remington: The Science and Practice of Pharmacy,” 20thEdition, Chapter 42, pp. 802-803 (2000).
Kataoka et al., “Totally Synthetic Polymer Gels Responding to External Glucose Concentration: Their Preparation and Application to On-Off Regulations of Insulin Release,”J. Am. Chem. Soc., vol. 120, pp. 12694-12695 (1998).
Kibbe, “Handbook of Pharmaceutical Excipients,” 3rdEdition, pp. 324-328 (2000).
Korcek et al., “Absolute Rate Constants for the Autoxidation of Organometallic Compounds, Part II. Benzylboranes and 1-Phenylethylboranes,”J. Chem. Soc., Perkin Trans. II, pp. 242-248 (1972).
Richardson et al., “A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma,”N. Engl. J. Med., vol. 348, No. 26, pp. 2609-2617 (1958).
Snyder et al., “Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes,”J. Am. Chem. Soc., vol. 80, pp. 3611-3615 (1958).
Stella et al., “Development of Parenteral Formulations of Experimental Cytoxic Agents. I. Rhizoxin (NSC-332598),”International Journal of Pharmaceutics, vol. 43, pp. 191-199 (1988).
Williams et al., “The Effects of Cooling Rate on Solid Phase Transitions and Associated Vial Breakage Occuring in Frozen Mannitol Solutions,”Journal of Parenteral Science&Technology, vol. 40, No. 4, pp. 135-141 (Jul. -Aug. 1986).
Williams et al., “Vial Breakage by Frozen Mannitol Solutions: Correlation with Thermal Characteristics and Effect of Stereoisomerism, Additives, and Vial Configuration,”Journal of Parenteral Science&Technologyvol. 45, No. 2, pp. 94-100 (Mar.-Apr. 1991).

Affiliated with

Also associated with

Rating

Formulation of boronic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation of boronic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation of boronic acid compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3550054